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Intermediate-risk cytogenetic acute myeloid leukemia with an internal tandem
duplication of (-ITD) is associated with a high risk of relapse, and is now a standard
indication for allogeneic stem cell transplantation. Nevertheless, most studies
supporting this strategy have been performed in young patients. To address the
benefit of allogeneic transplantation in the elderly, we made a selection from the
European Society for Blood and Marrow Transplantation registry of intermediate-risk
cytogenetic acute myeloid leukemia harboring -ITD in patients aged 60 or over and
transplanted from a related or unrelated donor between January 2000 and December
2015. Two hundred and ninety-one patients were identified. Most patients received a
reduced-intensity conditioning (82%), while donors consisted of an unrelated donor
in 161 (55%) patients. Two hundred and twelve patients received their
transplantation in first remission, 37 in second remission and 42 in a more advanced
stage of the disease. The 2-year leukemia-free survival rate was 56% in patients in
first remission, 22% in those in second remission and 10% in patients with active
disease, respectively (<0.005). Non-relapse mortality for the entire cohort was 20%.
In multivariate analysis, disease status at transplantation was the most powerful
predictor of worse leukemia-free survival, graft--host disease and relapse-free
survival, and overall survival. In this elderly population, age was not associated with
outcome. Based on the current results, allogeneic transplantation translates into a
favorable outcome in fit patients ≥ 60 with -ITD acute myeloid leukemia in first











































Publié sur Okina (http://okina.univ-angers.fr)
